Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Atea Pharmaceuticals, Inc. (AVIR)

3.395   -0.025 (-0.73%) 03-22 14:50
Open: 3.44 Pre. Close: 3.42
High: 3.49 Low: 3.31
Volume: 511,667 Market Cap: 283(M)

Technical analysis

as of: 2023-03-22 2:15:39 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 4.48     One year: 4.97
Support: Support1: 3.15    Support2: 2.62
Resistance: Resistance1: 3.83    Resistance2: 4.26
Pivot: 3.48
Moving Average: MA(5): 3.54     MA(20): 3.5
MA(100): 4.49     MA(250): 6.02
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 39.8     %D(3): 56.7
RSI: RSI(14): 37
52-week: High: 9.78  Low: 3.15
Average Vol(K): 3-Month: 496 (K)  10-Days: 958 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ AVIR ] has closed above bottom band by 27.9%. Bollinger Bands are 37.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.54 - 3.56 3.56 - 3.58
Low: 3.32 - 3.34 3.34 - 3.36
Close: 3.38 - 3.42 3.42 - 3.45

Company Description

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Headline News

Wed, 22 Mar 2023
Atea Pharmaceuticals Inc. (AVIR) Stock Records -25.81% Quarterly ... - The News Heater

Tue, 21 Mar 2023
A significant driver of top-line growth: Atea Pharmaceuticals Inc. (AVIR) - SETE News

Fri, 17 Mar 2023
Atea Pharmaceuticals Inc (AVIR) Stock: What Does the Chart Say Friday? - InvestorsObserver

Wed, 08 Mar 2023
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research - Yahoo Finance

Tue, 28 Feb 2023
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 ... - GlobeNewswire

Tue, 21 Feb 2023
Atea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023 - Yahoo Finance

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 83 (M)
Shares Float 70 (M)
% Held by Insiders 9.1 (%)
% Held by Institutions 70.5 (%)
Shares Short 1,800 (K)
Shares Short P.Month 1,480 (K)

Stock Financials

EPS -1.55
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.69
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -11.4
Return on Equity (ttm) -17.2
Qtrly Rev. Growth 0
Gross Profit (p.s.) -0.99
Sales Per Share 0
EBITDA (p.s.) -1.57
Qtrly Earnings Growth 0
Operating Cash Flow -121 (M)
Levered Free Cash Flow -82 (M)

Stock Valuations

PE Ratio -2.17
PEG Ratio 0
Price to Book value 0.43
Price to Sales 0
Price to Cash Flow -2.32

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.